Come ventilare il paziente ipossiemico acuto

1. Come ventilare il paziente ipossiemico acuto Andrea Vianello Fisiopatologia e Terapia Intensiva Respiratoria Ospedale – Università di Padova

2. Non-Invasive Ventilation has demonstrated good efficacy in reducing risk of intubation and mortality; however, some potential etiologies of acute respiratory failure are associated with ahigh risk of NIV failure, which may lead to great hospital mortality. Walkey AJ. Annals ATS 2013; 10:10-7

3. Talking about NIV failure: Epidemiology & Aetiology Remedies to avoid failure Transition to IMV: dancing in the dark

4. Rate of NIV failure is extremely differentaccording to study design, severity of illness and level of monitoring

5. Sixty-two RCTs including a total of 5870 patients Overall NIV failure: 16.3%

6. NIV – Real Life • Evaluation of all 449 patientsreceiving NPPV for a 1-yr periodforacuteoracute on chronic RF • CPE (n=97) • AECOPD (n=87) • non-COPD acutehypercapnic RF (n=35) • postextubation RF (n=95) • acutehypoxemic RF (n=144) • Intubation rate was 18%, 24%, 38%, 40%, and 60%,respectively • Hospital mortalityforpatientswithacutehypoxemic RF whofailed NPPV was 64% Schettino G. Crit Care Med 2008; 36:441-7

7. Schettino G, Crit Care Med 2008; 36:441-7

8. Epidemiology • Rationale:evidence supporting use of NIV varies widely for different causes of ARF. • Population:11,659,668 cases of ARF from the Nationwide Inpatient Sample during years 2000 to 2009; • Objectives:To compare utilization trends and outcomes associated with NIV in patients with and without COPD.

9. Acute respiratory failure-associated diagnosis Changing etiologies of ARF among patients receiving NIV

10. 20%ofpatientswithout a COPD diagnosiswhoreceived NIV IMV; • 13.4%ofpatientswith COPD whoreceived NIV IMV; • Patientsexperiencing NIV failurebeforetransitionto IMV hadgreater hospital mortalitythanthoseinitially on IMV

11. Rationale:The patterns and outcomes of NIV use in patients hospitalized for AECOPD nationwide are unknown. • Population:7,511,267 admissions for acute AE occurred from 1998 to 2008; • Objectives: To determine the prevalence and trends of NIV in AECOPD.

12. Use of NIPPV or IMV as first-line respiratory support in patients hospitalized with AECOPD

13. The percentage of patients transitioned from NIV to IMV ≈ 5% and did not increase from 1998 to 2008

14. Reasons for low rate of IMV use after NPPV, compared to clinical trial: • End of life decision to not accept IMV • Patients died before IMV could be started • Good selection of appropriate patients

15. High mortality rate (≈30%);↑ over time • OR for death:1.63, compared to those initially on IMV • ↑hospital stay

16. Reasons for high mortality rate in patients transitioned to IMV • Increased use of NIPPV in patients difficult to ventilate? • Continuation of NIPPV despite a lack of early improvement?

17. Aetiology of NIV failure Failure to adequately ventilate/oxygenate Delayed NIV treatment Inappropriate ventilatory technique Patient’s clinical condition B. Dependence on non-invasive support Lack of improvement of acute illness C. Complications

18. NIV trial inhypoxemic RFis justified if patients are carefully selected according to available guidelines, known risk factors and predictors for NIV failure. NIV failure is predicted by: • Advanced age • High acuity illness on admission (i.e. SAPS-II >34) • Acute respiratory distress syndrome • Community-acquired pneumonia with or without sepsis • Multi-organ system failure

19. NIV failure is predicted by: • Advanced age • High acuity illness on admission (i.e. SAPS-II >34) • Acute respiratory distress syndrome • Community-acquired pneumonia with or without sepsis • Multi-organ system failure

21. NIV in acute COPD: correlates for success • Retrospective analysis • 59 episodes of ARF in 47 COPD patients • NIV success: 46 • NIV failure: 13 • Predictors for NIV failure: • Higher PaCO2 at admission • Worse functional condition • Reduced treatment compliance • Pneumonia Ambrosino N, Thorax 1995;50:755-7

22. Summary of published studies for idiopathic pulmonary fibrosis patients in the ICU

23. Patientswith ALS • Retrospective analysis • 60 episodes of ARF in ALS patients managed by IMV via ETI • Initially on IMV: 31 • Transitioned from NIV to IMV: 29 • Dependence on NIV: 7 • Predictors for survival: • Age at admission ≥ 60 yrs < 60 yrs Percent survival of patients after tracheostomy, stratified by age group

24. NIV complications

25. Pneumotorax associated with long-term non-invasive positive pressure ventilation in Duchenne muscular dystrophy Vianello A , Arcaro, G, Gallan F, Ori C, Bevilacqua M Neuromusc Dis 2004;14:353-55

26. NIV complications

27. NIV reasons for failure Schettino G, Crit Care Med 2008; 36:441-7

28. Remedies to avoid NIV failure • Select patients carefully • Assess risk for failure; diagnosis, etc • Select comfortable mask • Optimize vent settings • Facilitate secretion removal • Treat agitation • Monitor closely in proper location • Assess response after 1 to 2 hrs

29. Remedies to avoid NIV failure Select patients carefully Assess risk for failure; diagnosis, etc Select comfortable mask Optimize vent settings Facilitate secretion removal

30. NIV should not be used in: • Respiratory arrest • Inability to tolerate the device, because of claustrophobia, agitation or uncooperativeness • Inability to protect the airway, due to swallowing impairment • Excessive secretions not sufficiently managed by clearance techniques • Recent upper airway surgery

31. COPD CHF/CPE PNA Asthma OHS NMD UAO post-op post-extub trauma ARDS MOF IPF Tight UAO

32. NIV fails more frequently for de novo ARF than for acute-on-chronic RF De Moule, Intensive Care Med 2006; 32:1756-65

33. Remedies to avoid NIV failure Select patients carefully Assess risk for failure; diagnosis, etc Select comfortable mask Optimize vent settings Facilitate secretion removal

34. Mask selection - a crucial issue! CO2rebreathing (50-100%) Noise (50-100%) Leak/Discomfort (30-50%) Claustrophobia (5-20%) Nasalskinlesions (2-50%)

35. The use of an oronasal mask is suggested rather than a nasal mask in patients who have ARF. • No recommendation about the use of an oronasal mask versus full face mask. Choose correct interface and size! Although there is no difference in ETI or mortality, RCT have reported that nasal mask is less tolerated than oronasal mask Girault, Crit Care Med 2009;37:124-31 Cuvelier, Intensive Care Med 2009;35:519-26

36. Remedies to avoid NIV failure Select patients carefully Assess risk for failure; diagnosis, etc Select comfortable mask Optimize vent settings Facilitate secretion removal

37. Ventilators Factors influencing preferred ventilator: Personal experience Location Available monitoring Leak compensation Trigger sensitivity Handling Flexibility Alarms ICU Ventilator Portable Ventilator

38. The golden rule does not apply to ventilator setting, however: • Pressure preset modes reduce the risk of failure and are recommended for COPD decompensated patients. French Guidelines for NIV treatment, 2008 • The “lung-protective” strategy may reduce the risk of barotrauma in patients with exacerbated ILD. Fernandez-Perez ER, Chest 2008; 133:1113-9

39. Remedies to avoid NIV failure Select patients carefully Assess risk for failure; diagnosis, etc Select comfortable mask Optimize vent settings Facilitate secretion removal

40. Enhancement of secretion clearance • Adequate hydration/humidification • Manually assisted cough • Cough assist • Antibiotics • Expectorants, mucolytics not of known value

41. Am J Phys Med Rehabil 2005;84:83-8

42. Transition to IMV: when is in the interest of a patient? • Hospital mortality: 64% (Schettino, 2008) • Mortality rate: 30%; prolonged hospitalization (Chandra, 2011) • Great hospital mortality (Walkey, 2013)

43. Transition to IMV(personal experience, 2011-2013)

44. Kaplan-Meier function of overall survival Median survival: 46 days (95% CI, 43 to 162)

45. Kaplan-Meier function of survival according to baseline condition Mean survival: NM/CW =305.58±36.9 COPD = 53.90±7.3 ILD = 31.13±7.8 ] p=0.0176 ] p<0.0001

46. Kaplan-Meier function of survival for dichotomus age (50 and >50) Median survival: 50 = 380.0 d (95%CI, 15.0 to n.c.) >50 = 45.0 d (95%CI,24.0 to 54.0) ] p=0.0071

47. Remarks • Mortality rate among patients transitioned to IMV is very high; • The outcome of patients with ILD is extremely poor. Should IPF/COPD patients be excluded from IMV after failing a NIV trial?

48. Conclusions • The boundaries for the use of NIV continue to expand, however: • The routine use of NIV in all patients with severe ARF is not yet supported • Caution should be used with NIV among patients at high risk of failure • Transitioning from NIV to IMV may not be in the interest of some categories of patients.